
    
      This trial will include patients who are not candidates for transplantation and above the age
      of 55. Treatment cycles will include (MP)melphalan (9 mg /sq.m/day d1-4), prednisolone (60
      mg/sq.m/d,d1-4) every six weeks for maximum 8 cycles. Patients will be randomised to (MPT)
      Thalidomide (1:1) 100 mg/day continuously. Cross-over to MPT is allowed if insufficient
      response is obtained in the MP arm. response will be evaluated every other cycle. At the end
      of 12 months of treatment patients will be followed until progress and death. Second line
      treatment is not defined.
    
  